Ropes & Gray Advised Pfizer in Deal for Two GSK Vaccines
June 23, 2015
Ropes & Gray advised Pfizer (NYSE: PFE) in its agreement to acquire quadrivalent meningitis ACWY vaccines Nimenrix and Mencevax from GlaxoSmithKline (NYSE: GSK) for a total consideration of about $130 million. The deal is expected to close in 2H. Nimenrix is designed to protect against Neisseria meningitides, while Mencevax is used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic.